Report Code: 12191 | Available Format: PDF | Pages: 378
Benign Prostatic Hyperplasia (BPH) Treatment Market Size Analysis Report by Type (Drug Treatment, Surgical Treatment), End User (Home Healthcare, Hospitals & Clinics) - Industry Analysis Forecast to 2030
- Report Code: 12191
- Available Format: PDF
- Pages: 378
- Report Description
- Table of Contents
- Market Segmentation
- Request Free Sample
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Type
1.5.2 Market Segmentation by End User
1.5.3 Market Segmentation by Region
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Designation
2.2.2 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
3.1 U.S.
3.2 Canada
3.3 Germany
3.4 France
3.5 U.K.
3.6 China
3.7 Japan
3.8 South Korea
3.9 India
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Definition of Market Segments
5.1 By Type
5.1.1 Drug Treatment
5.1.1.1 Alpha blockers
5.1.1.1.1 Alfuzosin
5.1.1.1.2 Doxazosin
5.1.1.1.3 Tamsulosin
5.1.1.1.4 Silodosin
5.1.1.1.5 Other alpha blockers
5.1.1.2 5-Alpha reductase inhibitors
5.1.1.2.1 Finasteride
5.1.1.2.2 Dutasteride
5.1.1.3 Others
5.1.2 Surgical Treatment
5.1.2.1 TURP
5.1.2.2 TUMT
5.1.2.3 TUNA
5.1.2.4 Laser therapy
5.1.2.5 Prostatic stenting
5.1.2.6 UroLift therapy
5.1.2.7 Rezûm therapy
5.1.2.8 Others
5.2 By End User
5.2.1 Home Healthcare
5.2.2 Hospitals & Clinics
Chapter 6. Industry Outlook
6.1 Market Dynamics
6.1.1 Trends
6.1.1.1 Technological advancements
6.1.1.2 Product approvals and launches
6.1.2 Drivers
6.1.2.1 Increasing geriatric male population
6.1.2.2 Rising prevalence of BPH
6.1.2.3 Surging awareness of BPH disorders
6.1.3 Impact Analysis of Drivers on Market Forecast
6.1.4 Restraints
6.1.4.1 Side-effects associated with BPH medication
6.1.4.2 Unfavorable healthcare reforms
6.1.5 Impact Analysis of Restraints on Market Forecast
6.2 Impact of COVID-19
6.3 Porter’s Five Forces Analysis
6.3.1 Bargaining Power of Buyers
6.3.2 Bargaining Power of Suppliers
6.3.3 Intensity of Rivalry
6.3.4 Threat of New Entrants
6.3.5 Threat of Substitutes
Chapter 7. Policy and Regulatory Landscape
7.1 Regulations for BPH Treatment Devices
7.1.1 North America
7.1.2 Europe
7.1.3 APAC
7.1.4 LATAM
7.1.5 MEA
7.2 Regulatory Framework for Drug Approval
7.2.1 U.S.
7.2.2 Europe
7.2.2.1 Centralized procedure
7.2.2.2 Mutual recognition procedure
7.2.2.3 Decentralized procedure
7.2.2.4 Nationalized procedure
7.2.3 Japan
Chapter 8. Global Market Size and Forecast
8.1 Overview
8.2 Market Revenue, by Type (2025–2030)
8.2.1 Global Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
8.2.1.1 Global benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
8.2.1.2 Global benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
8.2.2 Global Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
8.3 Market Revenue, by End User (2025–2030)
8.4 Market Revenue, by Region (2025–2030)
Chapter 9. North America Market Size and Forecast
9.1 Overview
9.2 Market Revenue, by Type (2025–2030)
9.2.1 North America Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
9.2.1.1 North America benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
9.2.1.2 North America benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
9.2.2 North America Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
9.3 Market Revenue, by End User (2025–2030)
9.4 Market Revenue, by Country (2025–2030)
Chapter 10. U.S. Market Size and Forecast
10.1 Market Revenue, by Type (2025–2030)
10.1.1 U.S. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
10.1.1.1 U.S. benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
10.1.1.2 U.S. benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
10.1.2 U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
10.2 Market Revenue, by End User (2025–2030)
Chapter 11. Canada Market Size and Forecast
11.1 Market Revenue, by Type (2025–2030)
11.1.1 Canada Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
11.1.1.1 Canada benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
11.1.1.2 Canada benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
11.1.2 Canada Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
11.2 Market Revenue, by End User (2025–2030)
Chapter 12. Europe Market Size and Forecast
12.1 Overview
12.2 Market Revenue, by Type (2025–2030)
12.2.1 Europe Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
12.2.1.1 Europe benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
12.2.1.2 Europe benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
12.2.2 Europe Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
12.3 Market Revenue, by End User (2025–2030)
12.4 Market Revenue, by Country (2025–2030)
Chapter 13. Germany Market Size and Forecast
13.1 Market Revenue, by Type (2025–2030)
13.1.1 Germany Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
13.1.1.1 Germany benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
13.1.1.2 Germany benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
13.1.2 Germany Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
13.2 Market Revenue, by End User (2025–2030)
Chapter 14. France Market Size and Forecast
14.1 Market Revenue, by Type (2025–2030)
14.1.1 France Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
14.1.1.1 France benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
14.1.1.2 France benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
14.1.2 France Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
14.2 Market Revenue, by End User (2025–2030)
Chapter 15. U.K. Market Size and Forecast
15.1 Market Revenue, by Type (2025–2030)
15.1.1 U.K. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
15.1.1.1 U.K. benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
15.1.1.2 U.K. benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
15.1.2 U.K. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
15.2 Market Revenue, by End User (2025–2030)
Chapter 16. APAC Market Size and Forecast
16.1 Overview
16.2 Market Revenue, by Type (2025–2030)
16.2.1 APAC Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
16.2.1.1 APAC benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
16.2.1.2 APAC benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
16.2.2 APAC Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
16.3 Market Revenue, by End User (2025–2030)
16.4 Market Revenue, by Country (2025–2030)
Chapter 17. China Market Size and Forecast
17.1 Market Revenue, by Type (2025–2030)
17.1.1 China Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
17.1.1.1 China benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
17.1.1.2 China benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
17.1.2 China Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
17.2 Market Revenue, by End User (2025–2030)
Chapter 18. Japan Market Size and Forecast
18.1 Market Revenue, by Type (2025–2030)
18.1.1 Japan Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
18.1.1.1 Japan benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
18.1.1.2 Japan benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
18.1.2 Japan Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
18.2 Market Revenue, by End User (2025–2030)
Chapter 19. South Korea Market Size and Forecast
19.1 Market Revenue, by Type (2025–2030)
19.1.1 South Korea Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
19.1.1.1 South Korea benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
19.1.1.2 South Korea benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
19.1.2 South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
19.2 Market Revenue, by End User (2025–2030)
Chapter 20. India Market Size and Forecast
20.1 Market Revenue, by Type (2025–2030)
20.1.1 India Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
20.1.1.1 India benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
20.1.1.2 India benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
20.1.2 India Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
20.2 Market Revenue, by End User (2025–2030)
Chapter 21. LATAM Market Size and Forecast
21.1 Overview
21.2 Market Revenue, by Type (2025–2030)
21.2.1 LATAM Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
21.2.1.1 LATAM benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
21.2.1.2 LATAM benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
21.2.2 LATAM Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
21.3 Market Revenue, by End User (2025–2030)
21.4 Market Revenue, by Country (2025–2030)
Chapter 22. MEA Market Size and Forecast
22.1 Overview
22.2 Market Revenue, by Type (2025–2030)
22.2.1 MEA Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2025–2030)
22.2.1.1 MEA benign prostatic hyperplasia alpha blockers market revenue, by type (2025–2030)
22.2.1.2 MEA benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2025–2030)
22.2.2 MEA Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2025–2030)
22.3 Market Revenue, by End User (2025–2030)
22.4 Market Revenue, by Country (2025–2030)
Chapter 23. Competitive Landscape
23.1 List of Market Players and Their Offerings
23.2 Market Share Analysis of Key Players
23.2.1 Global BPH Drugs Market
23.2.2 Global BPH Surgical Treatment Market
23.3 Competitive Analysis of Key Players
23.4 Product Comparison of Key Players
23.5 Recent Strategic Developments of Key Players
23.5.1 Partnerships & Acquisitions
23.5.2 Geographical Expansions
23.5.3 Product Launches
23.5.4 Other Developments
Chapter 24. Company Profiles
24.1 Astellas Pharma Inc.
24.1.1 Business Overview
24.1.2 Product and Service Offerings
24.1.3 Key Financial Summary
24.2 Alembic Pharmaceuticals Limited
24.2.1 Business Overview
24.2.2 Product and Service Offerings
24.2.3 Key Financial Summary
24.3 Unilab Inc.
24.3.1 Business Overview
24.3.2 Product and Service Offerings
24.4 Pharex Health Corporation
24.4.1 Business Overview
24.4.2 Product and Service Offerings
24.5 Biolitec AG
24.5.1 Business Overview
24.5.2 Product and Service Offering
24.6 Urologix LLC
24.6.1 Business Overview
24.6.2 Product and Service Offerings
24.7 Advin Health Care
24.7.1 Business Overview
24.7.2 Product and Service Offerings
24.8 Asclepion Laser Technologies GmbH
24.8.1 Business Overview
24.8.2 Product and Service Offerings
24.9 Pnn Medical A/S
24.9.1 Business Overview
24.9.2 Product and Service Offerings
24.10 Quanta Systems
24.10.1 Business Overview
24.10.2 Product and Service Offerings
24.11 Abbott Laboratories
24.11.1 Business Overview
24.11.2 Product and Service Offerings
24.11.3 Key Financial Summary
24.12 Asahi Kasei Corporation
24.12.1 Business Overview
24.12.2 Product and Service Offerings
24.12.3 Key Financial Summary
24.13 Richard Wolf GmbH
24.13.1 Business Overview
24.13.2 Product and Service Offerings
24.14 Boston Scientific Corporation
24.14.1 Business Overview
24.14.2 Product and Service Offerings
24.14.3 Key Financial Summary
24.15 KARL STORZ SE & Co. KG
24.15.1 Business Overview
24.15.2 Product and Service Offerings
24.16 Teleflex Incorporated
24.16.1 Business Overview
24.16.2 Product and Service Offerings
24.16.3 Key Financial Summary
24.17 Olympus Corporation
24.17.1 Business Overview
24.17.2 Product and Service Offerings
24.17.3 Key Financial Summary
24.18 Pfizer Inc.
24.18.1 Business Overview
24.18.2 Product and Service Offerings
24.18.3 Key Financial Summary
24.19 Merck & Co. Inc.
24.19.1 Business Overview
24.19.2 Product and Service Offerings
24.19.3 Key Financial Summary
24.20 Eli Lilly and Company
24.20.1 Business Overview
24.20.2 Product and Service Offerings
24.20.3 Key Financial Summary
24.21 GlaxoSmithKline plc
24.21.1 Business Overview
24.21.2 Product and Service Offerings
24.21.3 Key Financial Summary
24.22 Allergan plc
24.22.1 Business Overview
24.22.2 Product and Service Offerings
24.22.3 Key Financial Summary
24.23 IPG Photonics Corporation
24.23.1 Business Overview
24.23.2 Product and Service Offerings
24.23.3 Key Financial Summary
24.24 Sanofi
24.24.1 Business Overview
24.24.2 Product and Service Offerings
24.24.3 Key Financial Summary
24.25 Allium Medical Solutions Ltd.
24.25.1 Business Overview
24.25.2 Product and Service Offerings
24.26 SRS Medical
24.26.1 Business Overview
24.26.2 Product and Service Offerings
24.27 Convergent Laser Technologies
24.27.1 Business Overview
24.27.2 Product and Service Offerings
Chapter 25. Appendix
25.1 Sources and References
25.2 Related Reports
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 REGULATORY AND APPROVAL BODIES FOR MEDICAL DEVICES IN LATAM
TABLE 5 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 6 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 7 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 8 GLOBAL BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 9 GLOBAL BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 10 GLOBAL BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 11 GLOBAL BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 12 GLOBAL BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 13 GLOBAL BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 14 GLOBAL BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 15 GLOBAL BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 16 GLOBAL BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 17 GLOBAL BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 18 GLOBAL BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 19 GLOBAL BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 20 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 21 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 22 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 23 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY REGION, $M (2015–2021)
TABLE 24 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY REGION, $M (2025–2030)
TABLE 25 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY REGION, $M (2027–2030)
TABLE 26 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 27 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 28 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 29 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 30 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 31 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 32 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 33 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 34 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 35 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 36 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 37 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 38 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 39 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 40 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 41 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 42 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 43 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 44 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015–2021)
TABLE 45 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
TABLE 46 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 47 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 48 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 49 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 50 U.S. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 51 U.S. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 52 U.S. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 53 U.S. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 54 U.S. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 55 U.S. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 56 U.S. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 57 U.S. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 58 U.S. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 59 U.S. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 60 U.S. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 61 U.S. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 62 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 63 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 64 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 65 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 66 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 67 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 68 CANADA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 69 CANADA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 70 CANADA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 71 CANADA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 72 CANADA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 73 CANADA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 74 CANADA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 75 CANADA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 76 CANADA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 77 CANADA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 78 CANADA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 79 CANADA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 80 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 81 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 82 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 83 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 84 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 85 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 86 EUROPE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 87 EUROPE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 88 EUROPE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 89 EUROPE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 90 EUROPE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 91 EUROPE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 92 EUROPE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 93 EUROPE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 94 EUROPE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 95 EUROPE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 96 EUROPE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 97 EUROPE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 98 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 99 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 100 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 101 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015–2021)
TABLE 102 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
TABLE 103 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 104 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 105 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 106 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 107 GERMANY BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 108 GERMANY BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 109 GERMANY BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 110 GERMANY BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 111 GERMANY BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 112 GERMANY BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 113 GERMANY BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 114 GERMANY BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 115 GERMANY BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 116 GERMANY BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 117 GERMANY BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 118 GERMANY BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 119 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 120 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 121 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 122 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 123 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 124 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 125 FRANCE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 126 FRANCE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 127 FRANCE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 128 FRANCE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 129 FRANCE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 130 FRANCE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 131 FRANCE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 132 FRANCE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 133 FRANCE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 134 FRANCE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 135 FRANCE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 136 FRANCE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 137 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 138 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 139 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 140 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 141 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 142 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 143 U.K. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 144 U.K. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 145 U.K. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 146 U.K. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 147 U.K. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 148 U.K. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 149 U.K. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 150 U.K. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 151 U.K. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 152 U.K. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 153 U.K. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 154 U.K. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 155 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 156 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 157 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 158 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 159 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 160 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 161 APAC BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 162 APAC BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 163 APAC BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 164 APAC BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 165 APAC BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 166 APAC BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 167 APAC BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 168 APAC BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 169 APAC BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 170 APAC BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 171 APAC BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 172 APAC BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 173 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 174 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 175 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 176 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015–2021)
TABLE 177 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
TABLE 178 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 179 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 180 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 181 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 182 CHINA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 183 CHINA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 184 CHINA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 185 CHINA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 186 CHINA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 187 CHINA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 188 CHINA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 189 CHINA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 190 CHINA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 191 CHINA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 192 CHINA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 193 CHINA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 194 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 195 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 196 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 197 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 198 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 199 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 200 JAPAN BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 201 JAPAN BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 202 JAPAN BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 203 JAPAN BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 204 JAPAN BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 205 JAPAN BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 206 JAPAN BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 207 JAPAN BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 208 JAPAN BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 209 JAPAN BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 210 JAPAN BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 211 JAPAN BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 212 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 213 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 214 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 215 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 216 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 217 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 218 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 219 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 220 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 221 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 222 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 223 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 224 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 225 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 226 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 227 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 228 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 229 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 230 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 231 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 232 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 233 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 234 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 235 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 236 INDIA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 237 INDIA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 238 INDIA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 239 INDIA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 240 INDIA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 241 INDIA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 242 INDIA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 243 INDIA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 244 INDIA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 245 INDIA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 246 INDIA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 247 INDIA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 248 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 249 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 250 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 251 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 252 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 253 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 254 LATAM BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 255 LATAM BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 256 LATAM BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 257 LATAM BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 258 LATAM BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 259 LATAM BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 260 LATAM BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 261 LATAM BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 262 LATAM BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 263 LATAM BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 264 LATAM BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 265 LATAM BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 266 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 267 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 268 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 269 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015–2021)
TABLE 270 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
TABLE 271 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 272 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 273 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 274 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 275 MEA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 276 MEA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 277 MEA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 278 MEA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 279 MEA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 280 MEA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 281 MEA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 282 MEA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 283 MEA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 284 MEA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015–2021)
TABLE 285 MEA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
TABLE 286 MEA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2027–2030)
TABLE 287 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015–2021)
TABLE 288 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
TABLE 289 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2027–2030)
TABLE 290 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015–2021)
TABLE 291 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
TABLE 292 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2027–2030)
TABLE 293 LIST OF MARKET PLAYERS AND THEIR DEVICE OFFERINGS
TABLE 294 LIST OF MARKET PLAYERS AND THEIR DRUG OFFERINGS
TABLE 295 COMPETITIVE ANALYSIS OF KEY PLAYERS
TABLE 296 PRODUCT COMPARISON OF KEY PLAYERS
TABLE 297 ASTELLAS PHARMA INC. – AT A GLANCE
TABLE 298 ASTELLAS PHARMA INC. – KEY FINANCIAL SUMMARY
TABLE 299 ALEMBIC PHARMACEUTICALS LIMITED – AT A GLANCE
TABLE 300 ALEMBIC PHARMACEUTICALS LIMITED – KEY FINANCIAL SUMMARY
TABLE 301 UNILAB INC – AT A GLANCE
TABLE 302 PHAREX HEALTH CORPORATION – AT A GLANCE
TABLE 303 BIOLITEC AG. – AT A GLANCE
TABLE 304 UROLOGIX LLC – AT A GLANCE
TABLE 305 ADVIN HEALTH CARE – AT A GLANCE
TABLE 306 ASCLEPION LASER TECHNOLOGIES GMBH – AT A GLANCE
TABLE 307 PNN MEDICAL A/S – AT A GLANCE
TABLE 308 QUANTA SYSTEMS – AT A GLANCE
TABLE 309 ABBOTT LABORATORIES – AT A GLANCE
TABLE 310 ABBOTT LABORATORIES – KEY FINANCIAL SUMMARY
TABLE 311 ASAHI KASEI CORPORATION – AT A GLANCE
TABLE 312 ASAHI KASEI CORPORATION – KEY FINANCIAL SUMMARY
TABLE 313 RICHARD WOLF GMBH – AT A GLANCE
TABLE 314 BOSTON SCIENTIFIC CORPORATION – AT A GLANCE
TABLE 315 BOSTON SCIENTIFIC CORPORATION – KEY FINANCIAL SUMMARY
TABLE 316 KARL STORZ SE & CO. KG – AT A GLANCE
TABLE 317 TELEFLEX INCORPORATED – AT A GLANCE
TABLE 318 TELEFLEX INCORPORATED – KEY FINANCIAL SUMMARY
TABLE 319 OLYMPUS CORPORATION – AT A GLANCE
TABLE 320 OLYMPUS CORPORATION – KEY FINANCIAL SUMMARY
TABLE 321 PFIZER INC. – AT A GLANCE
TABLE 322 PFIZER INC. – KEY FINANCIAL SUMMARY
TABLE 323 MERCK & CO. INC. – AT A GLANCE
TABLE 324 MERCK & CO. INC. – KEY FINANCIAL SUMMARY
TABLE 325 ELI LILLY AND COMPANY – AT A GLANCE
TABLE 326 ELI LILLY AND COMPANY – KEY FINANCIAL SUMMARY
TABLE 327 GLAXOSMITHKLINE PLC – AT A GLANCE
TABLE 328 GLAXOSMITHKLINE PLC – KEY FINANCIAL SUMMARY
TABLE 329 ALLERGAN PLC – AT A GLANCE
TABLE 330 ALLERGAN PLC – KEY FINANCIAL SUMMARY
TABLE 331 IPG PHOTONICS CORPORATION – AT A GLANCE
TABLE 332 IPG PHOTONICS CORPORATION – KEY FINANCIAL SUMMARY
TABLE 333 SANOFI – AT A GLANCE
TABLE 334 SANOFI – KEY FINANCIAL SUMMARY
TABLE 335 ALLIUM MEDICAL SOLUTIONS LTD. – AT A GLANCE
TABLE 336 SRS MEDICAL – AT A GLANCE
TABLE 337 CONVERGENT LASER TECHNOLOGIES – AT A GLANCE
LIST OF FIGURES
FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT
FIG 2 RESEARCH METHODOLOGY
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
FIG 5 DATA TRIANGULATION APPROACH
FIG 6 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 7 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 8 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 9 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 10 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 11 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 12 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 13 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 14 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
FIG 15 VOICE OF INDUSTRY EXPERTS/KOLS
FIG 16 BARGAINING POWER OF BUYERS
FIG 17 BARGAINING POWER OF SUPPLIERS
FIG 18 INTENSITY OF RIVALRY
FIG 19 THREAT OF NEW ENTRANTS
FIG 20 THREAT OF SUBSTITUTES
FIG 21 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIAL STAGES)
FIG 22 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)
FIG 23 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU
FIG 24 MARKETING AUTHORIZATION PROCEDURES IN EU
FIG 25 CENTRALIZED PROCEDURE FOR DRUG APPROVAL
FIG 26 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL
FIG 27 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN
FIG 28 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
FIG 29 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 30 GLOBAL BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 31 GLOBAL BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 32 GLOBAL BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 33 GLOBAL BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 34 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 35 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY REGION, $M (2025–2030)
FIG 36 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
FIG 37 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 38 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 39 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 40 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 41 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 42 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 43 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
FIG 44 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 45 U.S. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 46 U.S. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 47 U.S. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 48 U.S. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 49 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 50 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 51 CANADA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 52 CANADA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 53 CANADA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 54 CANADA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 55 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 56 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
FIG 57 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 58 EUROPE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 59 EUROPE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 60 EUROPE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 61 EUROPE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 62 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 63 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
FIG 64 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 65 GERMANY BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 66 GERMANY BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 67 GERMANY BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 68 GERMANY BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 69 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 70 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 71 FRANCE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 72 FRANCE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 73 FRANCE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 74 FRANCE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 75 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 76 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 77 U.K. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 78 U.K. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 79 U.K. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 80 U.K. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 81 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 82 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
FIG 83 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 84 APAC BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 85 APAC BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 86 APAC BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 87 APAC BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 88 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 89 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
FIG 90 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 91 CHINA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 92 CHINA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 93 CHINA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 94 CHINA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 95 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 96 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 97 JAPAN BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 98 JAPAN BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 99 JAPAN BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 100 JAPAN BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 101 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 102 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 103 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 104 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 105 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 106 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 107 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 108 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 109 INDIA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 110 INDIA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 111 INDIA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 112 INDIA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 113 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 114 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
FIG 115 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 116 LATAM BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 117 LATAM BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 118 LATAM BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 119 LATAM BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 120 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 121 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
FIG 122 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
FIG 123 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 124 MEA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 125 MEA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 126 MEA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 127 MEA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2025–2030)
FIG 128 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2025–2030)
FIG 129 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2025–2030)
FIG 130 GLOBAL BPH DRUGS MARKET SHARE OF KEY PLAYERS (2023)
FIG 131 GLOBAL BPH SURGICAL TREATMENT MARKET SHARE OF KEY PLAYERS (2023)
FIG 132 ASTELLAS PHARMA INC. – REVENUE SPLIT BY GEOGRAPHY (2023)
FIG 133 ALEMBIC PHARMACEUTICALS LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 134 ABBOTT LABORATORIES – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 135 ASAHI KASEI CORPORATION – REVENUE SPLIT BY BUSINESS SECTOR AND GEOGRAPHY (2023)
FIG 136 BOSTON SCIENTIFIC CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 137 TELEFLEX INCORPORATED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 138 OLYMPUS CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 139 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 140 MERCK & CO. INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 141 ELI LILLY AND COMPANY – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2023)
FIG 142 GLAXOSMITHKLINE PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 143 ALLERGAN PLC – REVENUE SPLIT BY SEGMENT (2023)
FIG 144 IPG PHOTONICS CORPORATION – REVENUE SPLIT BY GEOGRAPHY (2023)
FIG 145 SANOFI – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to Analyst
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws